The Impact of Geographic Atrophy on Daily Behaviors of Individuals

  • Research type

    Research Study

  • Full title

    Understanding Behavioral Milestones in the Daily Life of People with Geographic Atrophy

  • IRAS ID

    198615

  • Contact name

    Amanda Spangler

  • Contact email

    amanda.spangler@edelman.com

  • Sponsor organisation

    Genentech Inc., a Member of Roche Group

  • Clinicaltrials.gov Identifier

    N/A, N/A

  • Duration of Study in the UK

    0 years, 6 months, 1 days

  • Research summary

    Genentech has sponsored this study to better understand the lives of patients with geographic atrophy. Geographic atrophy is an eye condition that leads to blindness, typically among the elderly. Currently, there is very little known about the experience of living with the condition and how it impacts the daily lives of patients. Genentech is in one of the final stages of developing a drug that helps slow down the progression of geographic atrophy, and would like to understand the experience of living with the condition from a patient’s perspective. Note that this study does not involve giving participant's medication of any kind.

    This study takes place in four countries around the world; one of which is the United Kingdom. In each country, five patients aged 65 and older will be observed and interviewed in their homes by an experienced researcher (field investigator) about their lifestyles and how it might be impacted by geographic atrophy. In addition, the participants will be filmed with a video camera throughout the interview. All of this research data will eventually be analyzed by experienced data analysts to identify key findings and themes.

  • REC name

    London - City & East Research Ethics Committee

  • REC reference

    16/LO/0398

  • Date of REC Opinion

    24 Mar 2016

  • REC opinion

    Further Information Favourable Opinion